Durvalumab increases overall survival in stage III non-small-cell lung cancer

The immune checkpoint inhibitor durvalumab significantly improves survival in people with stage III non-small-cell lung cancer, interim trial results published in The  New England Journal of Medicine have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research